Spruce Biosciences, Inc.

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team

Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™